EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

IL-21- and CXCL9-engineered GPC3-specific CAR-T cells combined with PD-1 blockade enhance cytotoxic activities against hepatocellular carcinoma

Shanshan Chen, Fusheng Gong, Shijia Liu, Yunqing Xie, Xingming Ye, Xiaowei Lin, Xiangru Wang, Qiuhong Zheng, Qinying Liu, Yang Sun

Clinical and Experimental Medicine · 2024

DOI: 10.1007/s10238-024-01473-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2024. Verfasst von Shanshan Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Provincial Key Laboratory of Tumor Biotherapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, …. Hauptthemen laut MEDLINE: Glypicans, Interleukins, Carcinoma, Hepatocellular, Immunotherapy, Adoptive. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Startup Fund for Scientific Research, Fujian Medical University, Sciences Foundation of Fujian University Cancer Hospital, Natural Science Foundation of Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The application of CAR-T cells in solid tumors poses several challenges, including poor T cell homing ability, limited infiltration of T cells and an immunosuppressive tumor environment. In this study, we developed a novel approach to address these obstacles by designing GPC3-specific CAR-T cell that co-express IL-21 and CXCL9 (21 × 9 GPC3 CAR-T cells) and blocking the PD-1 expression on it. The proliferation, cell phenotype, cytokine secretion and cell migration of indicated CAR-T cells were evaluated in vitro. The cytotoxic activities of genetically engineered CAR-T cells were accessed in vitro and in vivo. Compared to conventional GPC3 CAR-T cells, the 21 × 9 GPC3 CAR-T cells demonstrated superior proliferation, cytokine secretion and chemotaxis capabilities in vitro. Furthermore, when combined with PD-1 blockade, the 21 × 9 GPC3 CAR-T cells exhibited enhanced proliferation, cytokine secretion and enrichment of effector T cells such as CTL, NKT and TEM cells. In xenograft tumor models, the PD-1 blocked 21 × 9 GPC3 CAR-T cells effectively suppressed HCC xenograft growth and increased T cell infiltration. Overall, our study successfully generated GPC3 CAR-T cells expressing both IL-21 and CXCL9, demonstrated that combining PD-1 blockade can further enhance CAR-T cell function by promoting proliferation, cytokine secretion, chemotaxis and antitumor activity. These findings present a hopeful and potentially effective strategy for GPC3-positive HCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlypicansInterleukinsCarcinoma, HepatocellularImmunotherapy, AdoptiveLiver NeoplasmsProgrammed Cell Death 1 ReceptorChemokine CXCL9Receptors, Chimeric AntigenAnimalsHumansMiceXenograft Model Antitumor AssaysCell ProliferationCell Line, TumorInterleukin-21

Stichwörter der Autor:innen

CAR-TCXCL9GPC3HCCIL-21PD-1

Substanzen

GlypicansInterleukinsInterleukin-21Programmed Cell Death 1 ReceptorGPC3 protein, humanChemokine CXCL9Receptors, Chimeric AntigenCXCL9 protein, humanPDCD1 protein, human

Autor:innen und Institutionen

  • Fujian Provincial Key Laboratory of Tumor Biotherapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
  • Xiamen Humanity Hospital, Xiamen, 361003, China.
  • Fujian Provincial Key Laboratory of Tumor Biotherapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China. sunyangfjch@163.com.
  • Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China. sunyangfjch@163.com.

Förderung

  • Startup Fund for Scientific Research, Fujian Medical University
  • Sciences Foundation of Fujian University Cancer Hospital
  • Natural Science Foundation of Fujian Province
  • Fujian Provincial Health Technology Project
  • Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province, China
  • Joint Funds for the Innovation of Science and Technology, Fujian Province, China

Zitieren

APA

Chen, S., Gong, F., Liu, S., Xie, Y., Ye, X., Lin, X., Wang, X., Zheng, Q., Liu, Q., & Sun, Y. (2024). IL-21- and CXCL9-engineered GPC3-specific CAR-T cells combined with PD-1 blockade enhance cytotoxic activities against hepatocellular carcinoma. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01473-2

Vancouver

Chen S, Gong F, Liu S, Xie Y, Ye X, Lin X, et al. IL-21- and CXCL9-engineered GPC3-specific CAR-T cells combined with PD-1 blockade enhance cytotoxic activities against hepatocellular carcinoma. Clinical and Experimental Medicine. 2024. doi:10.1007/s10238-024-01473-2

BibTeX
@article{Chen2024,
  author = {Chen, Shanshan and Gong, Fusheng and Liu, Shijia and Xie, Yunqing and Ye, Xingming and Lin, Xiaowei and Wang, Xiangru and Zheng, Qiuhong and Liu, Qinying and Sun, Yang},
  title = {IL-21- and CXCL9-engineered GPC3-specific CAR-T cells combined with PD-1 blockade enhance cytotoxic activities against hepatocellular carcinoma},
  journal = {Clinical and Experimental Medicine},
  year = {2024},
  doi = {10.1007/s10238-024-01473-2}
}
Kostenlos starten →